US pharma giant Merck & Co (NYSE: MRK) has announced results from the Phase III KEYNOTE-091 trial investigating Keytruda (pembrolizumab).
The study met one of its dual primary endpoints of disease-free survival (DFS) for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer (NSCLC) following surgical resection regardless of PD-L1 expression.
Based on an interim analysis review conducted by an independent Data Monitoring Committee, adjuvant treatment with Keytruda resulted in a statistically-significant and clinically-meaningful improvement in DFS compared with placebo in the all-comer population of patients with stage IB-IIIA NSCLC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze